With respect to vaccination programs against human papillomavirus (HPV), Australia is unique in several respects. First, the scientific breakthrough of making virus-like particles (VLPs), the technology underpinning all current HPV vaccines, was made in Australia by Fraser and Zhou. Second, although comparable bodies to review the cost-effectiveness of drugs exist in other countries, the Pharma...

Since January 2008, the Italian Regions, in accordance with their organizational programme, have launched the offer of free human anti-papillomavirus vaccine (HPV) to 12-year-olds, with the possibility to extend this offer to other age groups. With the beginning of this vaccination campaign, a widespread scientific debate developed concerning certain aspects which are still disputed. In our opi...

www.thelancet.com Vol 385 March 28, 2015 1173 As a clinician who has witnessed the devastating impact of the HIV/AIDS epidemic since the 1980s, Sheena McCormack is enthusiastic about her latest project, the UK Medical Research Council (MRC) PROUD study. As lead investigator, she has been investigating the eff ect of pre-exposure prophylaxis (PrEP) to protect against HIV infection in high-risk m...

The rate and speed with which cancer biology discoveries translate into clinical practice have importance for oncologists, researchers, policy makers. A prior study found that among 101 science articles claiming a highly promising result translation, only 19 of (18.8%) interventions had positive randomized trials, whereas five been licensed use median follow-up 12 years.1Contopoulos-Ioannidis D...

BACKGROUND The ARTISTIC (A Randomised Trial In Screening To Improve Cytology) trial originally reported after two rounds of primary cervical screening with human papillomavirus (HPV). Extended follow-up of the randomised trial cohort through a third round could provide valuable insight into the duration of protection of a negative HPV test, which could allow extended screening intervals. If HPV...